AstraZeneca Plc.

astrazeneca plc. - All News and Analysis

• Pharma Roundup: Lilly's Prasugrel in Europe, AstraZeneca's $900 Million Deal, and More

  BNET - 2008-12-19

  EMEA backs Lilly's prasugrel, AZ pays $900 million for MAP partnership, Targanta lays off 85, Vertex's new hepatitis C drug may fetch $75,000. by John Maas

  Tags: AstraZeneca Plc., Pharmaceutical Company, EMEA, European Medicines Agency, Federal Government, Government, John Maas

• AstraZeneca to Target Nexium at Babies Under 1 Year Old

  BNET - 2008-12-19

  AstraZeneca has submitted a new drug application asking for approval to market Nexium for babies less than one year old. The company believes the drug is an appropriate short-term, second-line treatment for gastroesophageal reflux disease GERD. The application raises some interesting questions. It is well-known that babies throw up and...

  Tags: AstraZeneca Plc., Baby, GERD, Sales Strategy, Federal Government, Sales Force Management, Productivity, Sales, Government, Jim Edwards

• Pharma Roundup: Glaxo, Cardio R&D, and Dynavax; Abbott, Ibis, and Isis; and More

  BNET - 2008-12-18

  GSK's new cardiovascular clinical trial and Dynavax partnership; Abbott's purchase of Ibis; AZ's potential Nobel conflict of interest; Charles Nemeroff's unending absurdity. by John Maas

  Tags: AstraZeneca Plc., Antitrust, GlaxoSmithKline Plc., Corporate Law, Business Structures, Security, Business Operations, Finance, John Maas

• Pharma Roundup: Bayer Boosts R&D, AstraZeneca Outsources, Titan Execs Leave, and More

  BNET - 2008-12-15

  Bayer boosts spending on research and development, AstraZeneca contracts with India's Infosys for IT support, Titan loses two execs, biotech acquisitions increase. by John Maas

  Tags: AstraZeneca Plc., Bayer AG, R&D, Outsource, Research & Development, Biotechnology, Supply Chain Management (SCM), Business Operations, Enterprise Software, Software, John Maas

• AstraZeneca's Role in Nobel Prizes Is Questioned

  BNET - 2008-12-14

  UPDATE -- AstraZeneca failed to respond has now responded to BNET's request for comment, see below. The company also provided a statement to Pharmalot. The company confirmed its sponsorship of Nobel organizations but denied it had influenced the judges: "Because the Nobel Committee of Karolinska Institute, and not the Nobel companies,...

  Tags: AstraZeneca Plc., AZ, Details, Corporate Governance, Business Operations, Corporate Law, Jim Edwards

• Pharma Roundup: Infinity and AstraZeneca Split, Schering & Merck's PR Blunder, and More

  BNET - 2008-12-11

  A fond farewell between Infinity and AstraZeneca, a dubious PR honor for S-P and Merck over Vytorin, Lilly's ImClone-related costs mount, generics cost less. by John Maas

  Tags: AstraZeneca Plc., Merck & Co. Inc., MedImmune Inc., AZ, Public Relations, Business Structures, Marketing, Corporate Communications, Finance, John Maas

• The History of AstraZeneca's Mismarketing of Seroquel

  BNET - 2008-12-05

  AstraZeneca knew as far back as 2000 that Seroquel, its atypical antipsychotic, could cause diabetes in users. Since then, 15,000 consumers have sued the company. Documents describing AZ's early knowledge of Seroquel's risks surfaced in court, according to Bloomberg. In one document, AZ Global Safety Officer Wayne Geller concluded there...

  Tags: AstraZeneca Plc., FDA, Seroquel, Liaison, Sales Strategy, Federal Government, Sales Force Management, Sales, Government, Jim Edwards

• Abraxis Split Closes Door on a Rocky Patch for AstraZeneca

  BNET - 2008-11-26

  The split between AstraZeneca and Abraxis over their copromotion of cancer drug Abraxane was expected among some Abraxis reps since August of this year. Now it's official. The end of the agreement comes as the patent on Casodex expires in April 2009 and the company this week saw mixed results...

  Tags: AstraZeneca Plc., Abraxis, AZ, Sales Strategy, Sales Force Management, Sales, Jim Edwards

• Pharma Roundup: AstraZeneca and Teva Mend Fences, Barbara Ryan's M&A Speculation, and More

  BNET - 2008-11-25

  AstraZeneca and Teva settle a potentially-acrimonious patent battle. Barbara Ryan speculates on pharma M&A. EU criticizes "strategic patenting." Indonesia wants drug production facilities from Big Pharma. by John Maas

  Tags: AstraZeneca Plc., Pfizer Inc., M&A, Pharmaceutical Company, Indonesia, Mergers & Acquisitions, Outsourcing, Investment, Finance, It Operations, Business Operations, Outsourcing & Subcontracting, John Maas

• Pharma Roundup: Novartis Pipeline, AstraZeneca Layoffs, and More

  BNET - 2008-11-20

  Novartis pipeline, AstraZeneca layoffs, Merck's self-proclaimed goodness, lessons for pharma from Detroit. by John Maas

  Tags: AstraZeneca Plc., Layoff, Blog, Novartis AG, Pharmaceutical Company, Blogging, Internet, John Maas

• How AstraZeneca's U.S. Sales Reps Avoided the Current Round of Layoffs

  BNET - 2008-11-20

  AstraZeneca staff in the U.S. dodged a bullet this morning as the company announced 1,400 layoffs -- but none of them in America. The job losses will come instead in the U.K., Spain, Belgium and Sweden. AZ's explanation of the move was a masterpiece in cynical management-speak and news-burying. Its...

  Tags: Sweden, AstraZeneca Plc., Layoff, Sales Force, AZ, Sales Strategy, Sales Force Management, Workforce Management, Supply Chain Management (SCM), Sales, Human Resources, Enterprise Software, Software, Jim Edwards

• Pharma Roundup: Lawsuit for Roche, Teva Troubles for AstraZeneca, and More

  BNET - 2008-11-19

  Roche must pay in lawsuit, Teva aiming for AstraZeneca's customers, AstraZeneca's new U.S. president, and Novartis in Cambridge. by John Maas

  Tags: AstraZeneca Plc., Lawsuit, Roche Holding AG, John Maas, Teva, AZ, Federal Government, Government

• Pharma Roundup: AstraZeneca's Crestor Success, Pfizer's Chantix Problems, and More

  BNET - 2008-11-10

  Highly encouraging results on AZ's Crestor, UK drug regulators echo Chantix suicide concerns, OTC drug marketers struggle, Lilly CEO highlights three "gorillas" dogging pharma. by John Maas

  Tags: AstraZeneca Plc., Pfizer Inc., Pharmaceutical Company, John Maas, Brand, Gorilla, Branding, Sales Strategy, Marketing, Sales

• AstraZeneca's Cardiovascular Drug: Risks Up, Risks Down

  Seeking Alpha - 2008-11-10

  Derek Lowe submits: AstraZeneca AZN took a pretty big risk in running a trial as big as the JUPITER one, but it seems to have paid off for them. As everyone has been reading, it appears that their Crestor rosuvastatin lowers the risk of cardiovascular events in patients with...

  Tags: AstraZeneca Plc., Cholesterol, Seeking Alpha, Derek Lowe, Security, Biotech

• AstraZeneca Allegedly Recruits Tigger and Eeyore to Sell Seroquel

  BNET - 2008-11-06

  Some reps at AstraZeneca -- the ones urging their colleagues to use Tigger and Eeyore to sell the antipsychotic Seroquel -- just don't learn. Last year, AZ got itself embroiled in a federal investigation after one rep urged his colleagues to regard oncology docs' offices as "big buckets of money."...

  Tags: AstraZeneca Plc., Disney Corp., Patient, Tigger, Sales Strategy, Sales Force Management, Sales, Jim Edwards

• Zacks Industry Rank Analysis Highlights: Abbot Laboratories, AstraZeneca, Chattem, Cubist Pharmaceuticals and ViroPharma

  - 2008-10-23

  CHICAGO -- Zacks.com releases the latest Zacks Industry Rank. Stocks featured in this week's analysis includes Abbott Laboratories (NYSE: ABT), AstraZeneca (NYSE: AZN), Chattem (Nasdaq: CHTT), Cubist Pharmaceuticals (Nasdaq: CBST) and ViroPharma (Nasdaq: VPHM). To see the Zacks Industry Rank and the trend in earnings estimates revisions for more...

  Tags: Abbott Laboratories Inc., analyst, AstraZeneca Plc., brokerage, FINANCE, Investment, Nasdaq Stock Market Inc., New York Stock Exchange, newsletter, stock

• AstraZeneca and Columbia University Medical Center Sign Strategic Research Collaboration in Neurosciences; Focus on New Approaches to Treat Depression & Anxiety

  - 2008-10-15

  WILMINGTON, Del. and NEW YORK, Oct. 15 /PRNewswire-FirstCall/ -- AstraZeneca and Columbia University Medical Center today announced a new research collaboration to examine how neurogenesis -- the creation of new neuronal cells - in adults might offer novel approaches to treating depression and anxiety. For more than...

  Tags: AstraZeneca Plc., Benefits, Collaboration, Columbia University, depression, Groupware, HEALTHCARE, SOFTWARE

• Zacks Analyst Blog Highlights: AstraZeneca PLC, Phase Forward, Omnicom Group, Acorda Therapeutics and Digital River, Inc

  - 2008-10-10

  CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AstraZeneca PLC (NYSE: AZN), Phase Forward (NASDAQ: PFWD), Omnicom Group (NYSE:...

  Tags: analyst, AstraZeneca Plc., blog, FINANCE, Investment, MARKETING, Nasdaq Stock Market Inc., New York Stock Exchange, newsletter, revenue, stock

• Pharma Roundup: AstraZeneca Wins Web Traffic, Genentech Wins "Best Employer," and More

  BNET - 2008-10-10

  AstraZeneca's Nexium is most-visited drug website, Genentech voted best place to work, fewer DDMAC warning letters over time, GSK execs talk research. by John Maas

  Tags: AstraZeneca Plc., Web, Pharmaceutical Company, Genentech Inc., Research & Development, Federal Government, Biotechnology, Business Operations, Government, John Maas

• Teva Sues AstraZeneca Over Crestor: $2.8 Billion on the Line

  BNET - 2008-10-09

  Teva, the generic maker, is suing AstraZeneca, the holder of the original Crestor patent, claiming that AZ is somehow infringing on rights Teva acquired to the drug back in March 2007. The Crestor patent isn't supposed to expire until 2016 -- well beyond the industry's looming patent...

  Tags: AstraZeneca Plc., Patent, Teva, AZ, Jim Edwards